Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 4, 2007, Pages 631-636

  Tuttle, Katherine R ^a,d   McGill, Janeti B ^b   Haney, Douglas J ^c   Lin, Toni E ^c   Anderson, Pamela W ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE C; RUBOXISTAURIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; KIDNEY; MALE; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME;

DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; KIDNEY; MALE; MALEIMIDES; MIDDLE AGED; PROTEIN KINASE C; TIME FACTORS;

EID: 34548836596     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00840207     Document Type: Article

References (28)

1. Klein R, Klein BEK, Moss SE: The Wisconsin epidemiological study of diabetic retinopathy: A review. Diabetes Metab Rev 5: 559-570, 1989
2. Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, Taylor HR, Hamman RFL: Eye Diseases Prevalence Research Group: The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 122: 552-563, 2004
3. Javitt JC, Aiello LP, Chiang Y, Ferris FL 3rd, Canner JK, Greenfield S: Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 17: 909-917, 1994
4. Henricsson M, Sellman A, Tyrberg M, Groop L: Progression to proliferative retinopathy and macular oedema requiring treatment. Assessment of the alternative classification of the Wisconsin Study. Acta Ophthalmol Scand 77: 218-223, 1999
5. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 91: 1464-1474, 1984
6. Ballone E, Colagrande V, DiNicola M, DiMascio R, DiMascio C, Capani F: Probabilistic approach to developing nephropathy in diabetic patients with retinopathy. Stat Med 22: 3889-3897, 2003
7. United States Renal Data System: Annual data report: Incidence and prevalence. Am J Kidney Dis 49: S68-S84, 2007
8. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49: S42-S61, 2007
9. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820,2001
10. Candido R, Allen TJ: Haemodynamics in microvascular complications in type 1 diabetes. Diabetes Metab Res Rev 18: 286-304, 2002
11. Sheetz MJ, King GL: Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288: 2579-2588, 2002
12. Curtis TM, Scholfield CN: The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetes Metab Res Rev 20: 28-43, 2004
13. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stratum LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272: 728-731, 1996
14. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14: 439-447, 2000
15. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW: The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28: 2686-2690, 2005
16. The PKC-DRS2 Study Group: Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113: 2221-2230, 2006
17. The PKC-DRS Study Group: The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: Initial results of the protein kinase C beta inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54: 2188-2197, 2005
18. The PKC-DMES Study Group: Effect of ruboxistaurin, a PKC beta isoform-selective inhibitor, in patients with diabetic macular edema: 30-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 125: 318-324, 2007
19. Levey AS, Coresh J, Greene T, Stevens LA, Zhang Y, Hendriksen S, Kusek JW, Van Lente F; for the Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254, 2006
20. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976
21. Kelly DJ, Zhang Y, Hepper C, Gow RM, Jaworski K, Kemp BE, Wilkinson-Berka JL, Gilbert RE: Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52: 512-518, 2003
22. Tuttle KR, Anderson PW: A novel potential therapy for diabetic nephropathy and vascular complications: Protein kinase C beta inhibition. Am J Kidney Dis 42: 456-465, 2003
23. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 65: 2309-2320, 2004
24. McGill JB, King GL, Berg PH, Price KL, Kles KA, Bastyr EJ, Hyslop DL: Clirtical safety of the selective PKC beta inhibitor, ruboxistaurin. Expert Opin Drug Saf 5: 835-845, 2006
25. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
26. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
27. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
28. Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, Larson TS: Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis 43: 112-119, 2004